Elevated risk of prostate cancer among men with lynch syndrome

Journal of Clinical Oncology

Volumn 31, Issue 14, 2013, Pages 1713-1718

  Raymond, Victoria M ^a   Mukherjee, Bhramar ^a   Wang, Fei ^a   Huang, Shu Chen ^a   Stoffel, Elena M ^a,c   Kastrinos, Fay ^c,d   Syngal, Sapna ^c   Cooney, Kathleen A ^a,b   Gruber, Stephen B ^a,e  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d NewYork Presbyterian Hospital   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6;

ADULT; AGED; ARTICLE; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER RISK; CONTROLLED STUDY; GENE MUTATION; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; MISMATCH REPAIR; POPULATION; POPULATION RISK; PRIORITY JOURNAL; PROSTATE CANCER; COMPARATIVE STUDY; GENETIC PREDISPOSITION; GENETICS; HETEROZYGOTE; INCIDENCE; MIDDLE AGED; PENETRANCE; PROSTATE TUMOR; RISK; UNITED STATES; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DNA MISMATCH REPAIR; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; ODDS RATIO; PENETRANCE; PROSTATIC NEOPLASMS; RISK; UNITED STATES;

MLCS; MLOWN;

EID: 84879468424     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.44.1238     Document Type: Article

References (33)

1. Stoffel E, Mukherjee B, Raymond VM, et al: Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. Gastroenterology 137:1621-1627, 2009
2. Aarnio M, Mecklin JP, Aaltonen LA, et al: Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int J Cancer 64:430-433, 1995
3. Aarnio M, Sankila R, Pukkala E, et al: Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 81:214-218, 1999
4. Dinh TA, Rosner BI, Atwood JC, et al: Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population. Cancer Prev Res (Phila) 4:9-22, 2011
5. Bonadona V, Bonaïti B, Olschwang S, et al: Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA 305:2304-2310, 2011
6. van der Post RS, Kiemeney LA, Ligtenberg MJ, et al: Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers. J Med Genet 47:464-470, 2010
7. Dores GM, Curtis RE, Toro JR, et al: Incidence of cutaneous sebaceous carcinoma and risk of associated neoplasms: Insight into Muir-Torre syndrome. Cancer 113:3372-3381, 2008
8. Barrow E, Robinson L, Alduaij W, et al: Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: A report of 121 families with proven mutations. Clin Genet 75:141-149, 2009
9. National Cancer Institute: Surveillance, Epidemiology, and End Results. http://seer.cancer.gov
10. Soravia C, van der Klift H, Bründler MA, et al: Prostate cancer is part of the hereditary non-polyposis colorectal cancer (HNPCC) tumor spectrum. Am J Med Genet A 121A:159-162, 2003
11. Wagner DG, Gatalica Z, Lynch HT, et al: Neuroendocrine-type prostatic adenocarcinoma with microsatellite instability in a patient with lynch syndrome. Int J Surg Pathol 18:550-553, 2010
12. Kastrinos F, Mukherjee B, Tayob N, et al: Risk of pancreatic cancer in families with Lynch syndrome. JAMA 302:1790-1795, 2009
13. Lange K, Weeks D, Boehnke M: Programs for pedigree analysis: MENDEL, FISHER, and dGENE. Genet Epidemiol 5:471-472, 1988
14. Antoniou A, Pharoah PD, Narod S, et al: Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies. Am J Hum Genet 72:1117-1130, 2003
15. Burger M, Denzinger S, Hammerschmied CG, et al: Elevated microsatellite alterations at selected tetranucleotides (EMAST) and mismatch repair gene expression in prostate cancer. J Mol Med (Berl) 84:833-841, 2006
16. Chen Y, Wang J, Fraig MM, et al: Defects of DNA mismatch repair in human prostate cancer. Cancer Res 61:4112-4121, 2001
17. Ahman AK, Jonsson BA, Damber JE, et al: Low frequency of microsatellite instability in hereditary prostate cancer. BJU Int 87:334-338, 2001
18. Bauer CM, Ray AM, Halstead-Nussloch BA, et al: Hereditary prostate cancer as a feature of Lynch syndrome. Fam Cancer 10:37-42, 2011
19. da Silva FC, de Oliveira LP, Santos EM, et al: Frequency of extracolonic tumors in Brazilian families with Lynch syndrome: Analysis of a hereditary colorectal cancer institutional registry. Fam Cancer 9:563-570, 2011
20. Goecke T, Schulmann K, Engel C, et al: Genotype-phenotype comparison of German MLH1 and MSH2 mutation carriers clinically affected with Lynch syndrome: A report by the German HNPCC Consortium. J Clin Oncol 24:4285-4292, 2006
21. Scott RJ, McPhillips M, Meldrum CJ, et al: Hereditary nonpolyposis colorectal cancer in 95 families: Differences and similarities between mutation-positive and mutation-negative kindreds. Am J Hum Genet 68:118-127, 2001
22. Grindedal EM, Møller P, Eeles R, et al: Germline mutations in mismatch repair genes associated with prostate cancer. Cancer Epidemiol Biomarkers Prev 18:2460-2467, 2009
23. Maul JS, Warner NR, Kuwada SK, et al: Extracolonic cancers associated with hereditary nonpolyposis colorectal cancer in the Utah Population Database. Am J Gastroenterol 101:1591-1596, 2006
24. Win AK, Young JP, Lindor NM, et al: Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: A prospective cohort study. J Clin Oncol 30:958-964, 2012
25. Win AK, Lindor NM, Young JP, et al: Risks of primary extracolonic cancers following colorectal cancer in lynch syndrome. J Natl Cancer Inst 104:1363-1372, 2012
26. National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology: Prostate Cancer. http://www.nccn.org/professionals/physician-gls/f- guidelines.asp
27. Chou R, Croswell JM, Dana T, et al: Screening for prostate cancer: A review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 155:762-771, 2011
28. Thompson D, Easton DF: Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst 94:1358-1365, 2002
29. Ostrander EA, Udler MS: The role of the BRCA2 gene in susceptibility to prostate cancer revisited. Cancer Epidemiol Biomarkers Prev 17:1843-1848, 2008
30. Ewing CM, Ray AM, Lange EM, et al: Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med 366:141-149, 2012
31. Sargent DJ, Marsoni S, Monges G, et al: Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 28:3219-3226, 2010
32. Kim H, An JY, Noh SH, et al: High microsatellite instability predicts good prognosis in intestinal-type gastric cancers. J Gastroenterol Hepatol 26:585-592, 2011
33. Vilar E, Gruber SB: Microsatellite instability in colorectal cancer-the stable evidence. Nat Rev Clin Oncol 7:153-162, 2010